Table 3 Distribution of EGFR and HER2 biomarker IHC scores

From: Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

 

EGF100642

EGF104911

 

HER2 positivea (n =42)

HER2 negative ( n =22)

HER2 positivea (n =58)

HER2 IHC score, n (%)

 0

0

16 (73)

2 (3)

 1+

2 (5)

5 (23)

4 (7)

 2+

6 (14)

1 (5)

19 (33)

 3+

34 (81)

0 (0)

33 (57)

FISH amplification, n (%)

 Positive (â©Ÿ2)

39 (93)

1 (5)

53 (91)

 Negative (<1.8)

0

7 (32)

1 (2)b

 Non-evaluable

3 (7)c

13 (60)

3 (5)b

 Borderline (1.8–<2)

0

1 (5)d

1 (2)b

EGFR IHC score, n (%)

 0

30 (71)

19 (86)

46 (79)

 1+

7 (17)

2 (9)

10 (17)

 2+

5 (12)

1 (5)

1 (2)

 3+

0

0

1 (2)

  1. aHER2 eligibility was determined by site local laboratory data.
  2. bFISH-negative tumour was IHC 0; non-evaluable: one was IHC 0, one was IHC1+, one was IHC3+; borderline was IHC2+.
  3. cFISH non-evaluable tumours: one was IHC1+, one was IHC2+, one was IHC3+.
  4. dFISH borderline tumour was IHC 0.
Back to article page